Project Grant R01HL183221
Award Date 7/25/26
Completion Date 3/31/30
Dollars Obligated $773K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $1,574,578 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel targeted modified mRNA delivery strategies for donation after circulatory death (DCD) heart transplantation. The research addresses primary graft dysfunction (PGD), an ischemia-reperfusion injury occurring in approximately 35 percent of heart transplants and driven by hyper-inflammatory responses involving...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $249,000 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support post-transcriptional mechanisms of direct cardiac reprogramming. The project investigates how post-transcriptional regulation, including mRNA modification and translation, controls the conversion of cardiac fibroblasts into induced cardiomyocyte-like cells—a therapeutic approach to replace heart tissue lost to...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $787,297 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 4, 2026. The award funds research into vascular dysfunction and lung allograft health, specifically investigating the mechanisms of primary graft dysfunction (PGD)—an ischemia-reperfusion injury that occurs in approximately 35 percent of lung transplants. The research examines how inflammasome-mediated pyroptosis and endothelial...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $729,984 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 22, 2026. The award funds development of a three-dimensional real-time cardiovascular magnetic resonance imaging (3D RT CMR) reconstruction framework for imaging patients with cardiac arrhythmias. The proposed unsupervised reconstruction method, called Generative Prior with Multi-Dynamic Modeling (GEMM), enables highly accelerated 3D RT...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $453,834 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a tissue-selective modified mRNA delivery system for cardiac injury prevention and treatment. The recipient is developing CMSMRTS 143-122, a cardiomyocyte-selective modified mRNA system encapsulated in lipid nanoparticles for intravenous administration. The system targets acid ceramidase mRNA...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $249,000 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize genetic variants associated with doxorubicin-induced cardiotoxicity using induced pluripotent stem cell-derived cardiomyocytes. The award funds research to identify genetic determinants of doxorubicin-induced cardiotoxicity and enable precise risk stratification and cardioprotection. The principal investigator...
- The National Heart, Lung, and Blood Institute awarded the University of Cincinnati Sponsored Research Services Division $1.57 million on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on targeted rewiring of fibrosis drivers to enhance cardiac reprogramming following myocardial infarction. The research addresses excessive cardiac fibrosis resulting from the heart's repair response, which can lead to adverse remodeling and heart failure. The...
- The National Heart Lung and Blood Institute awarded the Beckman Research Institute of the City of Hope $813,810 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on nucleotide supplementation as a treatment strategy for ischemic heart disease and myocardial infarction. The project investigates the role of nucleotide balance in cardiomyocyte proliferation and aims to apply these findings for cardiac repair using large animal models....
- The National Institutes of Health National Heart Lung and Blood Institute awarded Brigham & Womens Hospital Inc. $1,242,222 on March 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate non-coding RNAs as therapeutic targets in chronic limb-threatening ischemia. The funded research addresses the pathophysiology of chronic limb-threatening ischemia (CLTI), a leading cause of amputation in adults affecting over 200 million people globally. The project will...
- The National Heart, Lung, and Blood Institute (NHLBI) within the National Institutes of Health awarded The Ohio State University $121,658 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how inflamed adipose tissue modulates vascular inflammation through adipocyte-derived extracellular vesicles. The funded research decodes the role of adipocyte-derived extracellular vesicle cargo in promoting cardiovascular disease risk in obese populations. The...